Presented for research literature review only Shaw AJ et al
Shel Wellness & Aesthetic Center, we offer innovative solutions to enhance your quality of life
All had started treatment with GLP-1 medications, including liraglutide (Victoza), semaglutide (Ozempic), or tirzepatide (Mounjaro), and had at least six months of follow-up data
As noted above, subcutaneous WAT is viewed as metabolically healthy, while increased visceral WAT mass has been identified as a risk factor for cardiovascular disease, type 2 diabetes mellitus (T2DM), and steatohepatitis [72,73]
Written by: Morgan Pennington , 03 Jun 2026 8 min read Reviewed and fact-checked: Semaglutide and Liraglutide are both medications that belong to the same family of drugs GLP-1 receptor agonists